Clinical Trials

Title   CO39722 A Phase III, Open-Label, Multicenter, Two-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizuman in Patients with Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Description   This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.
IRB Number   17-332
Treatment   Oncology - Melanoma
Status   Active
Start Date   08/31/2017
Principal Name   Arthur Frankel MD
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us